Severe loss of visceral fat and skeletal muscle after chemotherapy predicts poor prognosis in metastatic gastric cancer patients without gastrectomy

Wanjing Feng(Fudan University Shanghai Cancer Center), Xiaodong Zhu(Fudan University Shanghai Cancer Center), Chenchen Wang(Shanghai Medical College of Fudan University), Siyuan Chen(Jinan University), Weijian Guo, Xiaoying Zhao(Handan College), Mingzhu Huang(Fudan University Shanghai Cancer Center), Jinjia Chang(Fudan University Shanghai Cancer Center), Zhiyu Chen(Chongqing University), Hui Zhu(Shanghai Medical College of Fudan University)

Journal of Cancer

January 1, 2020

10.7150/jca.37270

Cited by 20

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer

|JAMA|2018|410

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2012|396

Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer

|JAMA|2023|384

CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

|Blood|2013|247